Atazanavir sulphate. Market analysis

Nature Reviews Drug Discovery

Volumn 2, Issue 11, 2003, Pages 857-858

  Raja, Aarti ^a   Lebbos, John ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FORTAVASE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIDEX EC; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC DISORDER; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0242521455     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1232     Document Type: Note

References (8)

1. Pomerantz, R. J. & Horn, D. L. Twenty years of therapy for HIV-1 infection. Nature Med. 9, 867-873 (2003).
2. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Discov. 2, 624-634 (2003).
3. Fässler, A. et al. Aza-peptide analogues as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability J. Med. Chem. 39, 3203-3216 (1996).
4. Priestle, J. P. et al. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 3, 381-389 (1995).
5. Bold, G. et al. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41, 3387-3401 (1998).
6. Robinson, B. S. et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44, 2093-2099 (2000).
7. FDA Drug Approvals List [online] (cited 9 September 2003). http://www.fda.gov/cder/foi/label/2003/21567_reyataz_lbl.pdf (2003).
8. Albrecht, M. A. et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N. Eng. J Med. 345, 398-407 (2001).